Tabriz University of Medical Sciences trial of inpatient intravenous urographin plus corticosteroid versus outpatient oral corticosteroid therapy in the Sudden Sensorineural Hearing Loss

Submission date 11/08/2006	Recruitment status No longer recruiting	Prospectively registeredProtocol
Registration date 13/10/2006	Overall study status Completed	Statistical analysis plan[X] Results
Last Edited 02/09/2021	Condition category Ear, Nose and Throat	Individual participant data

Plain English summary of protocolNot provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Javad Totonchi

Contact details

Daneshgah Street Imam Hospital ENT ward Tabriz Iran 0098411

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N/A

Study information

Scientific Title

Tabriz University of Medical Sciences trial of inpatient intravenous urographin plus corticosteroid versus outpatient oral corticosteroid therapy in the Sudden Sensorineural Hearing Loss

Acronym

SSHL trial

Study objectives

Sudden Sensorineural Hearing Loss is a diagnosis typically made if there is a greater than 20 dB hearing loss over at least three frequencies on audiometric testing.

Hypothesis:

In-hospital and vigorous treatment with intravenous corticosteroid and urographin will improve the outcome of patients with a sudden sensorineural hearing loss when compared to an outpatient oral corticosteroid therapy.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved by the Institutional Board Review and Ethics Committee, a section of Research Deputy of Faculty of Medicine at Tabriz University of Medical Sciences (TUMS).

Study design

Interventional, controlled clinical trial

Primary study design

Interventional

Secondary study design

Non randomised study

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Sudden Sensorineural Hearing Loss

Interventions

The trial is not a randomised one, as we had two groups: those hospitalised and those managed on outpatient. Hospitalisation was made on the basis of patient's request.

Inpatient group received intravenous corticosteroid and intravenous urographin, while outpatient group received oral corticosteroid.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Corticosteroid and urographin

Primary outcome measure

Hearing recovery as shown by pure tone average on audiogram.

Secondary outcome measures

No secondary outcome measures

Overall study start date

01/01/2003

Completion date

01/01/2005

Eligibility

Key inclusion criteria

- 1. Aged over 12 years
- 2. A greater than 20 dB hearing loss over at least three frequencies on audiometric testing

Participant type(s)

Patient

Age group

Not Specified

Sex

Both

Target number of participants

60

Total final enrolment

51

Key exclusion criteria

- 1. General medical condition necessitating a specific therapy
- 2. Incompliance to the medications

Date of first enrolment

01/01/2003

Date of final enrolment

01/01/2005

Locations

Countries of recruitment

Iran

Study participating centre Daneshgah Street

Tabriz Iran 0098411

Sponsor information

Organisation

Tabriz University of Medical Sciences (TUMS) (Iran)

Sponsor details

Danshgah Street Tabriz Iran 0098411

Sponsor type

University/education

ROR

https://ror.org/04krpx645

Funder(s)

Funder type

University/education

Funder Name

Tabriz University of Medical Sciences (TUMS) (Iran)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		01/07/2008	02/09/2021	Yes	No